Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Phase 1/2 Terminated
51 enrolled
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1/2 Terminated
101 enrolled
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Phase 1/2 Terminated
3 enrolled 9 charts
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase 1/2 Terminated
24 enrolled 15 charts
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1/2 Terminated
13 enrolled
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Phase 1/2 Terminated
67 enrolled
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Terminated
9 enrolled 11 charts
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2 Terminated
48 enrolled
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Phase 1/2 Terminated
3 enrolled
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Phase 1/2 Terminated
37 enrolled 30 charts
A Study of ONO-7475 in Patients With Acute Leukemias
Phase 1/2 Terminated
42 enrolled 47 charts
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1/2 Terminated
2 enrolled 14 charts
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Phase 1/2 Terminated
20 enrolled 13 charts
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Phase 1/2 Terminated
4 enrolled 9 charts
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Phase 1/2 Terminated
187 enrolled 8 charts
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Phase 1/2 Terminated
51 enrolled 18 charts
DC Vaccination in CML
Phase 1/2 Terminated
1 enrolled
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
30 enrolled 29 charts
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Phase 1/2 Terminated
1 enrolled
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Phase 1/2 Terminated
12 enrolled 20 charts
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Phase 1/2 Terminated
10 enrolled 28 charts
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Phase 1/2 Terminated
19 enrolled 11 charts
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Phase 1/2 Terminated
1 enrolled 4 charts
Cord Blood
Phase 1/2 Terminated
3 enrolled 8 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1/2 Terminated
25 enrolled
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
Phase 1/2 Terminated
3 enrolled
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Phase 1/2 Terminated
10 enrolled 13 charts
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
12 enrolled 14 charts
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Phase 1/2 Terminated
31 enrolled 24 charts
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase 1/2 Terminated
11 enrolled 11 charts
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Phase 1/2 Terminated
4 enrolled 8 charts
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells
Phase 1/2 Terminated
3 enrolled
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Phase 1/2 Terminated
5 enrolled
Bendamustine in Acute Leukemia and MDS
Phase 1/2 Terminated
27 enrolled 6 charts
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients
Phase 1/2 Terminated
30 enrolled